Description / Application
Axitinib is an indazole substituted at position 3 by a 2-(pyridin-2-yl)vinyl group and at position 6 by a 2-(N-methylaminocarboxy)phenylsulfanyl group. Used for the treatment of advanced renal cell carcinoma after failure of a first line systemic treatment. It has a role as an antineoplastic agent, a tyrosine kinase inhibitor and a vascular endothelial growth factor receptor antagonist. It is a member of benzamides, a member of pyridines, an aryl sulfide and a member of indazoles.
Identities
| Alternative Name | N-Methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide; Inlyta |
|---|---|
| Molecular Formula | C22H18N4OS |
| Molecular Weight | 386.5 |
| MFCD | MFCD09837898 |
Safety
| Pictograms |
|
|---|---|
| Signal Word | Warning |
| Hazard Statements | H302;H410 |
| Precautionary Statements | P264;P270;P273;P301+P312;P330;P391;P501 |